Expertise in
16
conditions

Dr. Celalettin Ustun

Hematology
Rush University Medical Center
1725 W Harrison St Ste 1010, 
Chicago, IL 
Offers Telehealth
29 Years of Experience
Expertise in
16
conditions
Rush University Medical Center
1725 W Harrison St Ste 1010, 
Chicago, IL 

Overview

Celalettin Ustun is a Hematologist in Chicago, Illinois. Dr. Ustun has been practicing medicine for over 29 years is highly rated in 16 conditions, according to our data. His top areas of expertise are Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 181 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in IL

Hospital Affiliations

Rush University Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Rush University Medical Center
1725 W Harrison St Ste 1010, Chicago, IL 60612
Other Locations
Office
1520 W Harrison St, Chicago, IL 60607

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
Relapse Prophylaxis With IL-15 Super Agonist N-803 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation
Relapse Prophylaxis With IL-15 Super Agonist N-803 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: November 03, 2023
Intervention Type: Drug
Study Drug: N-803 IL-15 Super Agonist Complex
Study Phase: Phase 2
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 27, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 3 Less Clinical Trials

181 Total Publications

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Journal: Blood advances
Published: March 12, 2025
Similar Doctors
Leo I. Gordon
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (3.2 miles away)
866-587-4322
Experience:
53+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Gordon has been practicing medicine for over 53 years is highly rated in 33 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
12
conditions
Dr. Santosh Saraf
Hematology
Expertise in
12
conditions
Dr. Santosh Saraf
Hematology

University Of Illinois Chicago Physician Group (Uicpg)

1801 W Taylor St, 
Chicago, IL 
 (0.4 miles away)
312-355-1700
Languages Spoken:
English
See accepted insurances

Santosh Saraf is a Hematologist in Chicago, Illinois. Dr. Saraf is highly rated in 12 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Rimas V. Lukas
Expertise in
25
conditions
Dr. Rimas V. Lukas
Hematology | Oncology
Expertise in
25
conditions
Dr. Rimas V. Lukas
Hematology | Oncology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
 (3.2 miles away)
312-695-4360
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rimas Lukas is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Lukas has been practicing medicine for over 24 years is highly rated in 25 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Gastrostomy.

Frequently Asked Questions about Dr. Celalettin Ustun

How do I make an appointment with Dr. Celalettin Ustun?

You can book an appointment with Dr. Celalettin Ustun by calling their office at 312-942-5904. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Celalettin Ustun a top-rated expert for Systemic Mastocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Celalettin Ustun is classified as an Elite expert for Systemic Mastocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Celalettin Ustun specialize in?

While Dr. Celalettin Ustun is a Hematology, they have specific expertise in Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Celalettin Ustun participate in research or clinical trials?

Yes. Dr. Celalettin Ustun has published 181 articles and abstracts on conditions like Systemic Mastocytosis. You can view a list of Dr. Celalettin Ustun's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Celalettin Ustun accept my insurance?

Dr. Celalettin Ustun accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 312-942-5904 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ustun's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile